Cas:92157-61-4 Ethyl 3-(4-hydroxy-3,5-dimethoxyphenyl)propanoate manufacturer & supplier

Chemical Name:Ethyl 3-(4-hydroxy-3,5-dimethoxyphenyl)propanoate

CAS.NO:92157-61-4

Synonyms:ethyl 3-[4-hydroxy-3,5-bis(methyloxy)phenyl]-2-propanoate;Dihydro-sinapinsaeure-aethylester;3-(4-Hydroxy-3,5-dimethoxy-phenyl)-propionsaeure-aethylester;3-(4-HYDROXY-3,5-DIMETHOXY-PHENYL)-PROPANOIC ACID ETHYL ESTER;3-(3,5-dimethoxy-4-hydroxyphenyl)propionic acid ethyl ester;3-(4-hydroxy-3,5-dimethoxy-phenyl)-propionic acid ethyl ester;sinapinic acid/H2 ethyl ester

Molecular Formula:C₁₃H₁₈O₅

Molecular Weight:254.27900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:64.99000

Exact Mass:254.11500

LogP:1.90510

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethyl 3-[4-hydroxy-3,5-bis(methyloxy)phenyl]-2-propanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,sinapinic acid/H2 ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,sinapinic acid/H2 ethyl ester Use and application,3-(3,5-dimethoxy-4-hydroxyphenyl)propionic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: He said it is “normal” for scientists and clinicians to discuss and debate data from experiments and clinical trials, but added those discussions have taken a turn “outside the boundaries of legitimate scientific deliberation.” [(η(1)-N-i-Pr)SiMe2CH2(η(5)-C13H8)]ZrCl2 manufacturers He said it is “normal” for scientists and clinicians to discuss and debate data from experiments and clinical trials, but added those discussions have taken a turn “outside the boundaries of legitimate scientific deliberation.” methyl 5,7-dimethyl-1-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)phthalazine-6-carboxylate suppliers He said it is “normal” for scientists and clinicians to discuss and debate data from experiments and clinical trials, but added those discussions have taken a turn “outside the boundaries of legitimate scientific deliberation.” N-(4-formylphenyl-2,6-d2)acetamide vendor & factory “From the new company, we’ll be able to provide customers with invaluable access to high-quality sterile fill and finish capacity, which is in huge demand globally,” Recipharm CEO Marc Funk said in a release. ,Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.”